Market Cap : 7.58 B | Enterprise Value : 6.53 B | PE Ratio : | PB Ratio : 8.93 |
---|
NAS:IONS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:IONS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ionis Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2020 was $-341.4 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2020 was $-486.8 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2020 was -58.48 (Mar. 2020 ) + -43.769 (Jun. 2020 ) + -43.091 (Sep. 2020 ) + -341.426 (Dec. 2020 ) = $-486.8 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline